Dodekin is a single-chain polypeptide consisting of the two subunits of the immunomodulatory payload IL12 fused to a human vascular targeting antibody in tandem diabody format. This novel format greatly improves the process development characteristics of immunocytokines containing multi-subunit cytokine payloads. IL12 has potent anti-cancer activity but its use as a therapeutic protein is limited by associated toxicities, by selectively delivering IL12 to the sub-endothelial extracellular matrix in tumor blood vessels it is possible to drastically improve the therapeutic index of this cytokine.
Quantitative biodistribution studies on Dodekin have shown preferential tumor uptake of the molecule compared to healthy organs and our pre-clinical work shows that the immunocytokine has a potent anti-tumor activity in several immunocompetent murine models of cancer. Dodekin is also able to induce long-lasting tumor eradication when administered in combination with paclitaxel, and potentiates the action of other therapeutic agents such immunological checkpoint inhibitors and immunocytokines, particularly those based around IL2, TNF or IL4. The product exhibits potent activity against subcutaneous, metastatic and orthotopic tumors.


Mosely (2017) Cancer Immunol. Res., 5, 29
Hemmerle & Neri (2014) Int. J. Cancer, 134, 467
Lasek et al. (2014) Cancer Immunol. Immunother., 63, 419
Pasche et al. (2012) Clin. Cancer Res., 12, 4092
Sommavilla et al. (2010) Protein Engin. Des. Sel., 23, 653
Gafner et al. (2006) Int. J. Cancer., 119, 2205
Halin et al. (2003) Cancer Res., 63, 3202
Halin et al. (2002) Nature Biotechnol., 20, 264
Castellani et al. (2002) Am. J. Pathol., 161, 1695

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.

I Accept Cookie Policy